Motavizumab
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Motavizumab
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.
has abstract
Motavizumab (proposed INN, tra ...... b for other treatments of RSV.
@en
موتافيزوماب هو جسم مضاد وحيد ا ...... رضع المعرضين لخطر مرتفع الشدة.
@ar
alternative name
Numax
@en
CAS number
677010-34-3
FDA UNII code
50Y163LK8Q
KEGG
Link from a Wikipage to an external page
Wikipage page ID
page length (characters) of wiki page
Wikipage revision ID
938,233,844
Link from a Wikipage to another Wikipage
ATC prefix
J06
@en
ATC suffix
BB17
@en
CAS number
ChemSpiderID
none
@en
KEGG
D06621
@en
mab type
mab
@en
molecular weight
Approximately 148 kg/mol
@en
protein bound
None
@en
routes of administration
i.v.
@en
source
zu/o
@en
target
RSV glycoprotein F
@en
tradename
Numax
@en
type
mab
@en
Verifiedfields
changed
@en
verifiedrevid
458,284,116
Watchedfields
changed
@en
wikiPageUsesTemplate
hypernym
comment
Motavizumab (proposed INN, tra ...... se II and III clinical trials.
@en
موتافيزوماب هو جسم مضاد وحيد ا ...... رضع المعرضين لخطر مرتفع الشدة.
@ar
label
Motavizumab
@en
موتافيزوماب
@ar